Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib

The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of imatinib. Other purposes of the study are to identify any side effects the drug may produce and to study the level of dasatanib in the blood and assess the efficacy of dasatanib in the treatment of leukemia.

Study Overview

• Status: Completed
• Conditions: Chronic Myeloid Leukemia; Philadelphia-Positive Myeloid Leukemia
• Intervention / Treatment: Drug: Dasatinib

• Study Type: Interventional
• Enrollment (Actual): 387
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • St. Leonards, New South Wales, Australia
      • Local Institution
  • Queensland
    • South Brisbane, Queensland, Australia
      • Local Institution
  • South Australia
    • Adelaide, South Australia, Australia
      • Local Institution
  • Victoria
    • East Mebourne, Victoria, Australia
      • Local Institution
    • Parkville, Victoria, Australia
      • Local Institution
• Austria
  • Wein, Austria
    • Local Institution
• Belgium
  • B-Leuven, Belgium
    • Local Institution
  • Bruxelles, Belgium
    • Local Institution
  • Edegem, Belgium
    • Local Institution
  • Yvoir, Belgium
    • Local Institution
• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
      • Local Institution
  • Ontario
    • Toronto, Ontario, Canada
      • Local Institution
  • Quebec
    • Montreal, Quebec, Canada
      • Local Institution
• Denmark
  • Aarhus, Denmark
    • Local Institution
• Finland
  • Helsinki, Finland
    • Local Institution
• France
  • Lille Cedex, France
    • Local Institution
  • Lyon Cedex 03, France
    • Local Institution
  • Nantes, France
    • Local Institution
  • Paris Cedex 10, France
    • Local Institution
  • Pessac, France
    • Local Institution
  • Poitiers Cedex, France
    • Local Institution
  • Strasbourg Cedex, France
    • Local Institution
• Germany
  • Hamburg, Germany
    • Local Institution
  • Leipzig, Germany
    • Local Institution
  • Mainz, Germany
    • Local Institution
  • Mannheim, Germany
    • Local Institution
• Ireland
  • Dublin, Ireland
    • Local Institution
  • Galway
    • Co Galway, Galway, Ireland
      • Local Institution
• Israel
  • Ramat-Gan, Israel
    • Local Institution
• Italy
  • Bari, Italy
    • Local Institution
  • Bologna, Italy
    • Local Institution
  • Milano, Italy
    • Local Institution
  • Napoli, Italy
    • Local Institution
  • Orbassano, Italy
    • Local Institution
  • Roma, Italy
    • Local Institution
• Korea, Republic of
  • Kyunggi-Do, Korea, Republic of
    • Local Institution
• Netherlands
  • Nijmegen, Netherlands
    • Local Institution
  • Rotterdam, Netherlands
    • Local Institution
• Norway
  • Trondheim, Norway
    • Local Institution
• Peru
  • Lima, Peru
    • Local Institution
• Singapore
  • Singapore, Singapore
    • Local Institution
• South Africa
  • Gauteng
    • Parktown, Gauteng, South Africa
      • Local Institution
    • Soweto, Gauteng, South Africa
      • Local Institution
• Spain
  • Barcelona, Spain
    • Local Institution
  • Madrid, Spain
    • Local Institution
• Sweden
  • Gothenburg, Sweden
    • Local Institution
  • Lund, Sweden
    • Local Institution
  • Stockholm, Sweden
    • Local Institution
  • Umea, Sweden
    • Local Institution
  • Uppsala, Sweden
    • Local Institution
• Switzerland
  • Basel, Switzerland
    • Local Instituion
• United Kingdom
  • Central
    • Glasgow, Central, United Kingdom
      • Local Institution
  • Greater London
    • London, Greater London, United Kingdom
      • Local Institution
• United States
  • California
    • Anaheim, California, United States
      • Local Institution
    • Loma Linda, California, United States
      • Local Institution
    • Los Angeles, California, United States
      • Local Institution
    • Stanford, California, United States
      • Local Institution
    • Vallejo, California, United States
      • Local Institution
  • Connecticut
    • Hartford, Connecticut, United States
      • Local Institution
  • District of Columbia
    • Washington, District of Columbia, United States
      • Local Institution
  • Florida
    • Jacksonville, Florida, United States
      • Local Institution
    • Tampa, Florida, United States
      • Local Institution
  • Georgia
    • Atlanta, Georgia, United States
      • Local Institution
  • Illinois
    • Chicago, Illinois, United States
      • Local Institution
  • Indiana
    • Indianapolis, Indiana, United States
      • Local Institution
  • Kansas
    • Kansas City, Kansas, United States
      • Local Institution
  • Maryland
    • Baltimore, Maryland, United States
      • Local Institution
  • Massachusetts
    • Boston, Massachusetts, United States
      • Local Institution
  • Michigan
    • Detroit, Michigan, United States
      • Local Institution
  • Missouri
    • Kansas City, Missouri, United States
      • Local Institution
    • St. Louis, Missouri, United States
      • Local Institution
  • Nebraska
    • Omaha, Nebraska, United States
      • Local Institution
  • New Jersey
    • Hackensack, New Jersey, United States
      • Local Institution
    • New Brunswick, New Jersey, United States
      • Local Institution
  • New York
    • New York, New York, United States
      • Local Institution
  • Oregon
    • Portland, Oregon, United States
      • Local Institution
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States
      • Local Institution
    • Pittsburgh, Pennsylvania, United States
      • Local Institution
  • South Carolina
    • Greenville, South Carolina, United States
      • Local Institution
  • Tennessee
    • Nashville, Tennessee, United States
      • Local Institution
  • Texas
    • Dallas, Texas, United States
      • Local Institution
    • Houston, Texas, United States
      • Local Institution
    • San Antonio, Texas, United States
      • Local Institution
    • Tyler, Texas, United States
      • Local Institution
  • Washington
    • Spokane, Washington, United States
      • Local Institution

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age of 18 years and older.
• Chronic myeloid leukemia (CML)
• Previous treatment with imatinib at a dose of >600 mg/day AND the development of progressive disease while receiving imatinib at that dose, OR
• CML with resistance to imatinib at a dose less than or equal to 600 mg/day with genetic mutation in the BCR-ABL gene that is associated with a high level of resistance to imatinib, OR
• Intolerance to imatinib at any dose
• Adequate organ function
• Women who are able to bear children must have a negative serum or urine pregnancy test. Adequate methods of contraception must be used throughout the study to avoid pregnancy for the entire interval of at least 1 month before and 3 months after completion of the study medication.

Exclusion Criteria:

• Woman who are pregnant or breastfeeding
• Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above
• Previous diagnosis of accelerated phase or blast crisis CML.
• Participants who are eligible and willing to undergo transplantation during the screening period
• Uncontrolled or significant cardiovascular disease
• Use of imatinib within 7 days.
• Use of interferon or cytarabine within 14 days
• Use of a targeted small-molecule anticancer agent within 14 days
• Use of certain medication that carry a known side effect risk of Torsade de Pointes - Certain medications that irreversibly inhibit platelet function or anticoagulants
• Prior therapy with dasatinib.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dasatinib, 70 mg twice daily (BID); Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.	Drug: Dasatinib; Tablets; oral; 70 mg BID, depending on response

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR)	Cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of Complete Cytogenetic Response (CCyR)-0% Ph+ metaphases plus Partial Cytogenetic Response (PCyR)-1% to 35% Ph+ metaphases.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Imatinib-intolerant Participants With MCyR	Determination of cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of CCyR-0% Ph+ metaphases and PCyR - 1% to 35% Ph+ metaphases.	Baseline to 2 years
Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months	Based on the Kaplan-Meier estimate of the duration of response. Determination of cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of Complete Cytogenetic Response (CCyR)-0% Ph+ metaphases and Partial Cytogenetic Response (PCyR) - 1% to 35% Ph+ metaphases.	12 and 24 Months
Median Time From First Dosing Date to Date of MCyR	MCyR is the combination of CCyR-0% Ph+ metaphases and PCyR - 1% to 35% Ph+ metaphases.	Baseline (within 4 weeks of Day 1) and every 12 weeks
Number of Participants With Complete Hematologic Response (CHR)	CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets <450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date.	Baseline (within 72 hours of start of therapy), weekly until Week 12, every 3 months until off-study
Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months	Based on the Kaplan-Meier estimate of the duration of response. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date.	12 and 24 months
Median Time From First Dosing Until CHR	CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets <450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date.	Baseline (within 72 hours of start of therapy), weekly until Week 12, every 3 months until off-study
Number of Participants With Major Molecular Response (MMR)	MMR is defined as ≤3 log reduction in BCR-ABL levels from the standardized baseline value of BCR-ABL:Control Gene ratio. The international ratio is obtained by multiplying BCR-ABL:Control gene ratio by the lab-specific conversion factor.	Baseline to 2 years
Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores	Health-related quality of life as measured by FACT-G, which comprises 27 questions in 4 domains: PWB, SWB, EWB, FWB. Total FACT-G score=summation of the 4 subscale scores and ranges from 0 to 108. Higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, & FWB score change of 3 or more, and SWB score change of 2 or more=minimal clinical important change. Baseline FACT-G measurements can be found in Baseline Characteristics.	Baseline, Day 29, every 4 weeks for the first 24 weeks, then every 12 weeks for the remainder of treatment, after end of treatment. Treatment continued until disease progression or development of toxicity or until other protocol-defined criteria.
Number of Imitanib-intolerant Participants With Drug-related Adverse Events (AEs), Death Within 30 Days of Last Dose, Death, and AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Grade 3-4 Thrombocytopenia, Grade 4-4 Neutropenia, and Any AE	AE=any new untoward medical occurrence or worsening of a preexisting medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)	Continuously, from baseline through 2 years
Number of Imitanib-resistant Participants With Drug-related AEs, Death Within 30 Days of Last Dose, Death, AEs Leading to Discontinuation, SAEs, Grade 3-4 Thrombocytopenia, Grade 3-4 Neutropenia, and Any AE	AE=any new untoward medical occurrence or worsening of a preexisting medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)	Continuously, from baseline through 2 years
Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib	Blood samples were collected for PK to be included in separate population PK analyses.	Day 8 of study; pretreatment through sample between 30 minutes and 3 hours following treatment, a sample between 5 hours and 8 hours following treatment and a sample at 12 hours, prior to the next dose.

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb

Publications and helpful links

General Publications

• Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30. Erratum In: Blood. 2007 Sep 1;110(5):1438.
• Muller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 3;114(24):4944-53. doi: 10.1182/blood-2009-04-214221. Epub 2009 Sep 24.

Study record dates

Study Major Dates

• Study Start: February 1, 2005
• Primary Completion (Actual): September 1, 2006
• Study Completion (Actual): April 1, 2008

Study Registration Dates

• First Submitted: January 12, 2005
• First Submitted That Met QC Criteria: January 12, 2005
• First Posted (Estimate): January 13, 2005

Study Record Updates

• Last Update Posted (Estimate): March 2, 2012
• Last Update Submitted That Met QC Criteria: February 29, 2012
• Last Verified: February 1, 2012

More Information

Terms related to this study

• Keywords: Chronic phase Philadelphia chromosome chronic myeloid leukemia (Ph+CML)
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Chromosome Aberrations; Translocation, Genetic; Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Dasatinib
• Other Study ID Numbers: CA180-013